Index -
P/E -
EPS (ttm) -2.97
Insider Own 0.35%
Shs Outstand 89.60M
Perf Week 11.73%
Market Cap 2.14B
Forward P/E 17.46
EPS next Y 1.37
Insider Trans 3.98%
Shs Float 89.28M
Perf Month 7.90%
Income -265.30M
PEG -
EPS next Q 0.25
Inst Own 116.54%
Short Float 6.88%
Perf Quarter 3.24%
Sales 2.88B
P/S 0.74
EPS this Y -59.92%
Inst Trans -
Short Ratio 4.44
Perf Half Y -40.46%
Book/sh 16.33
P/B 1.46
EPS next Y 144.03%
ROA -5.76%
Short Interest 6.14M
Perf Year -17.16%
Cash/sh 1.41
P/C 16.97
EPS next 5Y -8.80%
ROE -14.21%
52W Range 18.07 - 41.02
Perf YTD -31.52%
Dividend Est. -
P/FCF 9.46
EPS past 5Y -
ROI -10.01%
52W High -41.74%
Beta 0.52
Dividend TTM -
Quick Ratio 1.19
Sales past 5Y 6.72%
Gross Margin 13.98%
52W Low 32.26%
ATR (14) 1.08
Dividend Ex-Date -
Current Ratio 1.19
EPS Y/Y TTM -
Oper. Margin -1.81%
RSI (14) 60.01
Volatility 4.11% 4.52%
Employees 18000
Debt/Eq 0.82
Sales Y/Y TTM -
Profit Margin -9.22%
Recom 2.46
Target Price 24.10
Option/Short Yes / Yes
LT Debt/Eq 0.81
EPS Q/Q -504.33%
Payout -
Rel Volume 6.50
Prev Close 23.86
Sales Surprise -3.87%
EPS Surprise -144.44%
Sales Q/Q -16.47%
Earnings Aug 12 BMO
Avg Volume 1.38M
Price 23.90
SMA20 9.81%
SMA50 0.30%
SMA200 -21.01%
Trades
Volume 9,001,110
Change 0.17%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-08-24 Downgrade
Evercore ISI
Outperform → In-line
$31 → $27
Jul-24-24 Resumed
Barclays
Equal Weight
$30
Jun-06-24 Initiated
Goldman
Neutral
$28
May-29-24 Initiated
TD Cowen
Hold
$27
May-28-24 Initiated
Mizuho
Neutral
$27
Mar-22-24 Initiated
Robert W. Baird
Neutral
$43
Mar-06-24 Initiated
Deutsche Bank
Hold
$36
Jan-05-24 Initiated
William Blair
Mkt Perform
Jan-04-24 Initiated
Jefferies
Buy
$44
Dec-11-23 Upgrade
Citigroup
Neutral → Buy
$34 → $40
Dec-01-23 Upgrade
Evercore ISI
In-line → Outperform
$32 → $36
Nov-14-23 Upgrade
Barclays
Equal Weight → Overweight
$29 → $38
Oct-19-23 Initiated
Citigroup
Neutral
$32
Sep-14-23 Initiated
Evercore ISI
In-line
$31
Aug-16-23 Initiated
Barclays
Equal Weight
$29
Aug-07-23 Initiated
BofA Securities
Underperform
$27
Show Previous Ratings
Aug-13-24 12:58PM
(Morningstar Research) +10.88%
Aug-12-24 07:04PM
(Morningstar Research) -20.35%
07:00AM
Jul-17-24 07:00AM
Jul-11-24 08:42AM
08:00AM
Loading…
08:00AM
Jun-27-24 07:00AM
Jun-19-24 05:02PM
Jun-04-24 07:00AM
Jun-03-24 07:00AM
May-30-24 07:01PM
07:00AM
May-21-24 09:48AM
May-17-24 10:15PM
May-16-24 04:05PM
03:56PM
Loading…
May-15-24 03:56PM
May-14-24 06:43PM
03:01AM
May-13-24 06:50PM
(Morningstar Research) -14.90%
10:52AM
06:30AM
May-06-24 08:22AM
Apr-30-24 01:58PM
Apr-11-24 07:00AM
Mar-12-24 11:24AM
Mar-11-24 06:30AM
06:30AM
Feb-20-24 04:05PM
07:00AM
Jan-29-24 07:00AM
04:22PM
Loading…
Jan-09-24 04:22PM
Jan-08-24 07:00AM
Jan-05-24 04:53AM
Jan-04-24 08:00AM
Jan-02-24 07:00AM
Dec-13-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 08:33PM
(Morningstar Research) +5.05%
Nov-13-23 11:07AM
06:30AM
Nov-02-23 07:00AM
Oct-18-23 05:40AM
Oct-17-23 01:35PM
09:05AM
Oct-16-23 08:30PM
(The Wall Street Journal)
Oct-13-23 07:00AM
Oct-11-23 07:00AM
Oct-10-23 07:00AM
Oct-06-23 04:52AM
Sep-15-23 08:45PM
Sep-06-23 11:00AM
11:00AM
Aug-16-23 10:00AM
Aug-15-23 07:03AM
07:03AM
Aug-14-23 07:00AM
Aug-07-23 09:57AM
09:57AM
Jul-20-23 07:00AM
Jul-18-23 07:40AM
Jul-07-23 12:00PM
(The Wall Street Journal) -5.21%
Jun-28-23 06:08PM
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Morais Mark A. Chief Operating Officer Aug 19 '24 Option Exercise 0.00 11,312 0 36,464 Aug 20 05:37 PM Mcconnell Jill G. Chief Financial Officer Aug 19 '24 Option Exercise 0.00 11,312 0 38,194 Aug 20 05:36 PM Pike Thomas Chief Executive Officer Aug 19 '24 Option Exercise 0.00 125,691 0 183,518 Aug 20 05:34 PM Smith David Ross Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:24 PM NEUPERT PETER M Director Jul 18 '24 Option Exercise 0.00 6,354 0 28,350 Jul 19 05:23 PM Pesicka Edward A Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:23 PM ECKERT R ANDREW Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:22 PM Ray Amrit Director Jul 18 '24 Option Exercise 0.00 6,354 0 6,354 Jul 19 05:21 PM Hanson James S. General Counsel Jun 12 '24 Buy 25.30 2,000 50,600 7,475 Jun 12 06:28 PM Hanson James S. General Counsel Jun 03 '24 Option Exercise 0.00 7,706 0 7,706 Jun 03 07:08 PM Warren Amanda M. Chief Accounting Officer Jun 03 '24 Option Exercise 0.00 3,842 0 6,411 Jun 03 07:05 PM Mcconnell Jill G. Chief Financial Officer Jun 03 '24 Option Exercise 0.00 11,000 0 31,717 Jun 03 07:03 PM Morais Mark A. Chief Operating Officer Jun 03 '24 Option Exercise 0.00 11,000 0 29,406 Jun 03 07:01 PM Pike Thomas Chief Executive Officer May 29 '24 Buy 24.81 10,000 248,066 57,827 May 30 04:34 PM Larson Betty D Former Director Mar 30 '24 Option Exercise 0.00 6,354 0 6,354 Apr 01 06:33 AM Mcconnell Jill G. Chief Financial Officer Mar 04 '24 Option Exercise 0.00 20,776 0 26,815 Mar 06 06:42 PM Morais Mark A. Chief Operating Officer Mar 04 '24 Option Exercise 0.00 15,368 0 22,856 Mar 06 06:40 PM Mcconnell Jill G. Chief Financial Officer Feb 11 '24 Option Exercise 0.00 1,544 0 6,486 Feb 13 05:05 PM Warren Amanda M. Chief Accounting Officer Feb 11 '24 Option Exercise 0.00 1,068 0 2,935 Feb 13 05:03 PM Morais Mark A. Chief Operating Officer Feb 11 '24 Option Exercise 0.00 1,210 0 7,839 Feb 13 05:01 PM Mcconnell Jill G. Chief Financial Officer Feb 07 '24 Option Exercise 0.00 1,680 0 5,437 Feb 08 07:00 PM Warren Amanda M. Chief Accounting Officer Feb 07 '24 Option Exercise 0.00 1,182 0 2,272 Feb 08 06:58 PM Morais Mark A. Chief Operating Officer Feb 07 '24 Option Exercise 0.00 2,249 0 7,280 Feb 08 06:55 PM Mcconnell Jill G. Chief Financial Officer Feb 02 '24 Option Exercise 0.00 1,708 0 4,262 Feb 05 05:19 PM Warren Amanda M. Chief Accounting Officer Feb 02 '24 Option Exercise 0.00 1,046 0 1,449 Feb 05 05:17 PM Morais Mark A. Chief Operating Officer Feb 02 '24 Option Exercise 0.00 1,787 0 5,183 Feb 05 05:17 PM Pike Thomas Chief Executive Officer Jan 09 '24 Option Exercise 0.00 40,220 0 60,220 Jan 11 06:12 PM Morais Mark A. Chief Operating Officer Dec 15 '23 Option Exercise 0.00 406 0 3,891 Dec 15 05:41 PM
Index -
P/E -
EPS (ttm) -0.86
Insider Own 17.98%
Shs Outstand 51.93M
Perf Week 0.28%
Market Cap 377.23M
Forward P/E 31.78
EPS next Y 0.23
Insider Trans -0.97%
Shs Float 43.27M
Perf Month 0.56%
Income -44.77M
PEG -
EPS next Q -0.07
Inst Own 47.91%
Short Float 7.88%
Perf Quarter 167.79%
Sales 58.20M
P/S 6.48
EPS this Y 59.14%
Inst Trans -
Short Ratio 1.54
Perf Half Y 122.74%
Book/sh 0.47
P/B 15.32
EPS next Y 159.21%
ROA -36.31%
Short Interest 3.41M
Perf Year 364.29%
Cash/sh 1.15
P/C 6.21
EPS next 5Y -
ROE -109.01%
52W Range 1.08 - 7.19
Perf YTD 134.43%
Dividend Est. -
P/FCF -
EPS past 5Y 18.38%
ROI -73.22%
52W High -0.56%
Beta 1.68
Dividend TTM -
Quick Ratio 2.12
Sales past 5Y 18.67%
Gross Margin 89.44%
52W Low 562.04%
ATR (14) 0.08
Dividend Ex-Date -
Current Ratio 2.48
EPS Y/Y TTM 48.82%
Oper. Margin -65.09%
RSI (14) 84.40
Volatility 0.22% 0.31%
Employees 100
Debt/Eq 1.95
Sales Y/Y TTM -34.73%
Profit Margin -76.93%
Recom 3.00
Target Price 7.15
Option/Short Yes / No
LT Debt/Eq 1.49
EPS Q/Q -173.02%
Payout -
Rel Volume 0.00
Prev Close 7.15
Sales Surprise 1.78%
EPS Surprise 39.43%
Sales Q/Q -60.97%
Earnings Aug 08 BMO
Avg Volume 2.21M
Price 7.15
SMA20 0.36%
SMA50 26.34%
SMA200 77.29%
Trades
Volume 0
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-23 Upgrade
JP Morgan
Underweight → Neutral
$7 → $10
Jan-03-23 Reiterated
Needham
Buy
$32 → $31
Nov-04-21 Downgrade
JP Morgan
Neutral → Underweight
$20 → $19
Oct-15-21 Resumed
BTIG Research
Buy
$51
Sep-30-21 Downgrade
JP Morgan
Overweight → Neutral
$24 → $20
Nov-17-20 Downgrade
Raymond James
Strong Buy → Outperform
Jun-26-20 Initiated
ROTH Capital
Buy
$55
Jan-21-20 Reiterated
H.C. Wainwright
Buy
$72 → $82
Aug-08-19 Upgrade
JP Morgan
Neutral → Overweight
Feb-07-19 Initiated
B. Riley FBR
Buy
$55
Jan-23-19 Downgrade
JP Morgan
Overweight → Neutral
Dec-20-18 Initiated
Raymond James
Strong Buy
Nov-08-18 Reiterated
Needham
Buy
$76 → $74
Sep-10-18 Resumed
BTIG Research
Buy
$80
May-29-18 Initiated
H.C. Wainwright
Buy
$61
May-18-18 Reiterated
Needham
Buy
$42 → $60
Show Previous Ratings
Sep-20-24 11:08AM
Sep-18-24 08:54AM
Sep-05-24 06:30AM
Aug-08-24 12:13PM
(Pharmaceutical Technology)
07:40AM
06:30AM
Loading…
06:30AM
Aug-07-24 06:29AM
Aug-01-24 06:50PM
Jul-25-24 11:15AM
Jul-15-24 02:00PM
Jul-10-24 06:40AM
Jul-01-24 08:00AM
Jun-25-24 06:12AM
Jun-24-24 10:52AM
10:31AM
08:23AM
Loading…
08:23AM
07:16AM
06:30AM
Jun-05-24 07:00AM
May-28-24 06:30AM
May-23-24 05:06PM
May-22-24 10:00AM
06:30AM
May-02-24 10:43AM
03:09AM
May-01-24 11:04PM
(Thomson Reuters StreetEvents) +9.55%
05:50PM
09:33AM
07:54AM
07:40AM
06:30AM
Loading…
06:30AM
06:25AM
Apr-17-24 09:00AM
Apr-11-24 09:15AM
Apr-04-24 10:30AM
Apr-01-24 04:20PM
Mar-01-24 04:20PM
Feb-29-24 10:21AM
Feb-28-24 11:09PM
(Thomson Reuters StreetEvents) +38.75%
07:40AM
06:51AM
06:30AM
Feb-27-24 08:30AM
Feb-15-24 08:30AM
Feb-13-24 08:15AM
Feb-12-24 04:05PM
Jan-08-24 06:45AM
Jan-03-24 05:02PM
09:00AM
Jan-02-24 04:51PM
Dec-13-23 11:05PM
Dec-05-23 09:26AM
Dec-01-23 04:27PM
Nov-29-23 08:37PM
Nov-02-23 09:46AM
Nov-01-23 11:49PM
(Thomson Reuters StreetEvents) -18.79%
09:45AM
06:30AM
Oct-27-23 07:00AM
Oct-26-23 10:02AM
Oct-25-23 10:01AM
Oct-18-23 08:00AM
07:30AM
Oct-16-23 09:00AM
Sep-18-23 07:00AM
Sep-05-23 11:00AM
Sep-01-23 04:15PM
Aug-02-23 07:45AM
06:30AM
Jul-31-23 02:30PM
08:30AM
Jul-27-23 09:42AM
Jul-26-23 09:00AM
Jul-06-23 04:15PM
Jun-04-23 09:17AM
07:13AM
Jun-01-23 04:40PM
May-22-23 04:45PM
May-16-23 07:30AM
May-10-23 07:31AM
May-08-23 06:02AM
May-05-23 06:12AM
May-03-23 02:20PM
(American City Business Journals)
07:45AM
06:30AM
May-01-23 05:00PM
Apr-26-23 12:45PM
Apr-18-23 10:16AM
Apr-12-23 12:00PM
Apr-11-23 12:30PM
Mar-02-23 09:55PM
12:01AM
(Thomson Reuters StreetEvents)
Mar-01-23 07:55AM
06:30AM
Feb-28-23 02:10PM
Feb-22-23 10:00AM
Feb-17-23 07:40AM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-13-23 01:33PM
(American City Business Journals) -53.16%
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Perry Andrew Chief Commercial Officer Jul 05 '24 Sale 2.51 1,337 3,353 112,614 Jul 08 05:59 PM MURDOCK TERRY L Chief Operating Officer Jul 05 '24 Sale 2.51 2,475 6,207 128,012 Jul 08 05:58 PM Malik Rajesh Chief Medical Officer Jul 05 '24 Sale 2.51 2,475 6,207 159,312 Jul 08 05:57 PM Avagliano Mark Chief Business Officer Jul 05 '24 Sale 2.51 2,638 6,615 242,045 Jul 08 05:55 PM Umstead John W. V Chief Financial Officer Jul 05 '24 Sale 2.51 527 1,322 187,718 Jul 08 05:54 PM Bailey John E. (Jack) Jr. President and CEO Jul 05 '24 Sale 2.51 7,662 19,214 549,674 Jul 08 05:53 PM Thomas Monica R. Chief Legal & People Officer May 23 '24 Sale 4.27 5,826 24,864 109,825 May 24 04:15 PM Umstead John W. V Chief Financial Officer May 13 '24 Sale 4.79 8,151 39,034 153,245 May 15 04:11 PM MURDOCK TERRY L Chief Operating Officer May 13 '24 Sale 4.79 8,151 39,034 95,487 May 15 04:10 PM Malik Rajesh Chief Medical Officer May 13 '24 Sale 4.79 8,151 39,034 161,787 May 15 04:08 PM Avagliano Mark Chief Business Officer May 13 '24 Sale 4.79 8,151 39,034 209,683 May 15 04:07 PM Bailey John E. (Jack) Jr. President and CEO May 13 '24 Sale 4.79 37,258 178,421 452,336 May 15 04:06 PM Umstead John W. V Chief Financial Officer Mar 18 '24 Sale 3.02 6,547 19,752 123,896 Mar 20 04:32 PM Malik Rajesh Chief Medical Officer Feb 12 '24 Option Exercise 0.30 28,600 8,580 198,538 Feb 13 06:14 PM Malik Rajesh Chief Medical Officer Feb 12 '24 Sale 4.62 28,600 132,143 169,938 Feb 13 06:14 PM Umstead John W. V Chief Financial Officer Jan 03 '24 Sale 3.12 632 1,971 130,554 Jan 08 06:04 AM Umstead John W. V Chief Financial Officer Jan 04 '24 Sale 2.94 111 327 130,443 Jan 08 06:04 AM Malik Rajesh Chief Medical Officer Jan 03 '24 Sale 3.12 3,019 9,416 170,659 Jan 08 06:03 AM Malik Rajesh Chief Medical Officer Jan 04 '24 Sale 2.94 721 2,121 169,938 Jan 08 06:03 AM Perry Andrew Chief Commercial Officer Jan 03 '24 Sale 3.12 2,413 7,526 87,102 Jan 08 06:03 AM Bailey John E. (Jack) Jr. President and CEO Jan 03 '24 Sale 3.12 11,686 36,447 489,594 Jan 08 06:02 AM Avagliano Mark Chief Business Officer Jan 03 '24 Sale 3.12 3,360 10,480 118,555 Jan 08 06:02 AM Avagliano Mark Chief Business Officer Jan 04 '24 Sale 2.94 721 2,121 117,834 Jan 08 06:02 AM MURDOCK TERRY L Chief Operating Officer Jan 03 '24 Sale 3.12 3,019 9,416 104,359 Jan 08 06:00 AM MURDOCK TERRY L Chief Operating Officer Jan 04 '24 Sale 2.94 721 2,121 103,638 Jan 08 06:00 AM Bailey John E. (Jack) Jr. President and CEO Jan 02 '24 Sale 3.27 32,983 108,006 400,580 Jan 02 07:44 PM Malik Rajesh Chief Medical Officer Dec 11 '23 Option Exercise 0.36 33,839 12,081 157,817 Dec 13 04:45 PM Malik Rajesh Chief Medical Officer Dec 11 '23 Sale 3.41 33,839 115,522 136,378 Dec 13 04:45 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite